Atrial fibrillation and metformin treatment

Česká verzia

Authors: Andrej Dukát ¹; Milan Kriška ²; Ján Kyselovič ¹; Juraj Payer ¹
Authors place of work: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava ¹; Ústav farmakológie a klinickej farmakológie LF UK v Bratislave ²
Published in the journal: Forum Diab 2023; 12(1): 52-54
Category:

Summary

Last december Cell Reports Medicine brought significant paper, showing to metformin as a candidate drug for the patients with atrial fibrillation. Using the active comparator, a new design analysis of large-scale longitudinal electronic health record data, metformin use is significantly associated with a reduced risk of atrial fibrillation odds ratio: OR 0,48 (95% CI 0,36–0,54; p < 0,001) compared with standard treatment for diabetes. Metformin showed its benefits also among patients with infection of COVID-19. From its discovery one hundred years ago new data shows new indication for the clinical practice.

Zdroje

1. Han N, Hwang W, Tzelepis K et al. Indentification of SARS-CoV-2-induced pathways reveals drug repurposing strategies. Sci Adv 2021; 7(27): eabh3032. Dostupné z DOI: <http://dx.doi.org/10.1126/sciadv.abh3032>.

2. Wilke T, Groth A, Mueller S et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8,3 million patients. Europace 2013; 15(4): 486–493. Dostupné z DOI: <http://dx.doi.org/10.1093/europace/eus333>.

3. Piccini JP, Hammill BG, Sinner MF et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries. 1993–2007. Circ Cardiovasc Qual Outcomes 2012; 5(1): 85–93. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCOUTCOMES.111.962688>.

4. Benjamin EJ, Munter P, Alonso A et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019; 139(10): e56-e528. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000659>.

5. Benjamin EJ, Wolf PA, D´Agostino RB et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98(10): 946–952. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.98.10.946>.

6. Samol A, Masin M, Gellner R et al. Prevalence of unknown atrial fibrillation in patients with risk factors. Europace 2013; 15(5): 657–662. Dostupné z DOI: <http://dx.doi,org/10.1093/europace/eus366>.

7. Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution o the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2020; 42(5): 373–498. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaa612>.

8. Chao TF, Joung B, Takahashi Y et al. 2021 focused update consensus guidelines of the Asia Pacific heart rhythm society on stroke prevention in atrial fibrillation. Executive summary. Thromb Haemost 2022; 122(1): 20–47. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0041–1739411>.

9. Romiti GF, Proletti M, Bonini N et al. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF Registry Phase II and III. Thromb Haemost 2022; 122(12): 2030–2041. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0042–1756355>.

10. Dukát A, Gajdošík J, Kriška M, Payer J. Liečba metformínom vo vzťahu ku ochoreniu SARS-CoV-2. Forum Diab 2022; 11(1): 47–49.

11. Crouse AB, Grimes T, Li P et al. Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes. Front Endocrinol (Lausanne) 2021; 11: 600439. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2020.600439>.

12. Lai JC, Mao C, Zhou Y et al. Transcriptomics-based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation. Cell Rep Med 2022; 3(10): 100749. Dostupné z DOI: <http://dx.doi.org/10.1016/j.xcrm.2022.100749>.

13. Vinciguerra M, Olier I, Ortega-Martonelli S et al. New use for an old drug: Metformin and atrial fibrillation. Cell Rep Med 2022; 3(12): 100875. Dostupné z DOI: <http://dx.doi.org/10.1016/j.xcrm.2022.100875>.

14. Barzilai N, Crandall JP, Kritchevsky SB et al. Metformin as a tool to target aging. Cell Metab 2016; 23(6): 1060–1065. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmet.2016.05.011>.

15. Romiti GF, Pastori D, Rivera-Caravaca JM et al. Adherence to the „atrial fibrillation better care“ pathway in patients with atrial fibrillation: Impact on clinical outcomes-A syste-matic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122(3): 406–414. Dostupné z DOI: <http://dx.doi.org/10.1055/a-1515–9630>.

16. Dukát A, Kriška M, Kyselovič J et al. Metformín a fibrilácia predsiení. Interná Med 2022; 12: 523–525.